A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Bristol Myers Squibb has spent the most on M&A, R&D and licensing since 2017, and Eli Lilly the least. Guess which strategy is working best.
A second year of pandemic investments helped big pharma’s combined R&D bill surge above $100bn for the first time.
With Ferring filed and Seres preparing to do so, regulators' views on microbiome approaches to C difficile will soon be heard.
Roche, its coffers full from coronavirus test sales, ups its research spending – but Baxter cuts back.